ARCHIVES

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

This article is from The Cancer Letter archive.

Vol. 32 No. 28 | July 21, 2006

Download PDF Visit The Full Archive

Related Articles

In Sign-Off Of Two Orphan Drugs, ODAC Leaves Efficacy Interpretation To Docs

November 27, 1998

NRC considering “Escalated” Enforcement Action Against NIH

February 2, 1996

ACS Lists Challenges For Global Tobacco Control

January 22, 2010

BMS Award Honors Jordan; Matthews Media Wins $23 Million Contract From MCI.

April 6, 2001

DFCI Puts The Cancer Letter On Its Intranet For Employees.

February 11, 2000

Advocacy Groups Form Council To Lobby For Cancer Programs To Benefit Minorities

April 28, 1995